Lonza Group AG (LZAGF)
USD 740.0
(3.79%)
USD 740.0
(3.79%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 17.08 Billion CHF | -1.57% |
| 2022 | 17.35 Billion CHF | 5.45% |
| 2021 | 16.45 Billion CHF | 14.07% |
| 2020 | 14.42 Billion CHF | 4.25% |
| 2019 | 13.84 Billion CHF | -0.57% |
| 2018 | 13.92 Billion CHF | 0.95% |
| 2017 | 13.79 Billion CHF | 101.96% |
| 2016 | 6.82 Billion CHF | 9.28% |
| 2015 | 6.24 Billion CHF | -3.0% |
| 2014 | 6.44 Billion CHF | -1.53% |
| 2013 | 6.54 Billion CHF | -7.87% |
| 2012 | 7.1 Billion CHF | 1.14% |
| 2011 | 7.02 Billion CHF | 46.92% |
| 2010 | 4.77 Billion CHF | -3.36% |
| 2009 | 4.94 Billion CHF | 0.24% |
| 2008 | 4.93 Billion CHF | -0.38% |
| 2007 | 4.95 Billion CHF | 26.56% |
| 2006 | 3.91 Billion CHF | -9.67% |
| 2005 | 4.33 Billion CHF | 29.63% |
| 2004 | 3.34 Billion CHF | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 17.88 Billion CHF | 0.0% |
| 2024 Q1 | 17.88 Billion CHF | 4.69% |
| 2023 Q4 | 17.08 Billion CHF | 1.39% |
| 2023 Q1 | 17.67 Billion CHF | 1.82% |
| 2023 FY | 17.08 Billion CHF | -1.57% |
| 2023 Q3 | 16.84 Billion CHF | -4.66% |
| 2023 Q2 | 17.67 Billion CHF | 0.0% |
| 2022 Q2 | 16.74 Billion CHF | 0.0% |
| 2022 Q4 | 17.35 Billion CHF | 0.0% |
| 2022 FY | 17.35 Billion CHF | 5.45% |
| 2022 Q1 | 16.74 Billion CHF | 1.73% |
| 2022 Q3 | 17.35 Billion CHF | 3.66% |
| 2021 FY | 16.45 Billion CHF | 14.07% |
| 2021 Q3 | 16.45 Billion CHF | 8.56% |
| 2021 Q2 | 15.16 Billion CHF | 0.0% |
| 2021 Q1 | 15.16 Billion CHF | 5.07% |
| 2021 Q4 | 16.45 Billion CHF | 0.0% |
| 2020 Q3 | 14.42 Billion CHF | 3.46% |
| 2020 Q2 | 13.94 Billion CHF | 0.0% |
| 2020 Q4 | 14.42 Billion CHF | 0.0% |
| 2020 Q1 | 13.94 Billion CHF | 0.77% |
| 2020 FY | 14.42 Billion CHF | 4.25% |
| 2019 Q1 | 13.49 Billion CHF | -3.08% |
| 2019 Q3 | 13.84 Billion CHF | 2.59% |
| 2019 FY | 13.84 Billion CHF | -0.57% |
| 2019 Q2 | 13.49 Billion CHF | 0.0% |
| 2019 Q4 | 13.84 Billion CHF | 0.0% |
| 2018 Q3 | 13.92 Billion CHF | -0.6% |
| 2018 Q1 | 14 Billion CHF | 1.56% |
| 2018 Q4 | 13.92 Billion CHF | 0.0% |
| 2018 FY | 13.92 Billion CHF | 0.95% |
| 2018 Q2 | 14 Billion CHF | 0.0% |
| 2017 Q4 | 13.79 Billion CHF | -0.3% |
| 2017 FY | 13.79 Billion CHF | 101.96% |
| 2017 Q2 | 9.59 Billion CHF | 0.0% |
| 2017 Q1 | 9.59 Billion CHF | 40.47% |
| 2017 Q3 | 13.83 Billion CHF | 44.21% |
| 2016 Q3 | 6.82 Billion CHF | 8.52% |
| 2016 Q1 | 6.29 Billion CHF | 0.7% |
| 2016 FY | 6.82 Billion CHF | 9.28% |
| 2016 Q2 | 6.29 Billion CHF | 0.0% |
| 2016 Q4 | 6.82 Billion CHF | 0.0% |
| 2015 Q1 | 6.04 Billion CHF | -6.18% |
| 2015 Q4 | 6.24 Billion CHF | 0.0% |
| 2015 Q2 | 6.04 Billion CHF | 0.0% |
| 2015 Q3 | 6.24 Billion CHF | 3.39% |
| 2015 FY | 6.24 Billion CHF | -3.0% |
| 2014 FY | 6.44 Billion CHF | -1.53% |
| 2014 Q1 | 6.6 Billion CHF | 0.92% |
| 2014 Q2 | 6.6 Billion CHF | 0.0% |
| 2014 Q3 | 6.44 Billion CHF | -2.42% |
| 2014 Q4 | 6.44 Billion CHF | 0.0% |
| 2013 Q4 | 6.54 Billion CHF | 2.64% |
| 2013 FY | 6.54 Billion CHF | -7.87% |
| 2013 Q3 | 6.37 Billion CHF | -8.98% |
| 2013 Q2 | 7 Billion CHF | 0.0% |
| 2013 Q1 | 7 Billion CHF | -1.38% |
| 2012 Q2 | 7.01 Billion CHF | 0.0% |
| 2012 FY | 7.1 Billion CHF | 1.14% |
| 2012 Q4 | 7.1 Billion CHF | 0.0% |
| 2011 FY | 7.02 Billion CHF | 46.92% |
| 2011 Q4 | 7.02 Billion CHF | 0.0% |
| 2011 Q2 | 4.4 Billion CHF | 0.0% |
| 2010 Q4 | 4.77 Billion CHF | 0.0% |
| 2010 Q2 | 4.97 Billion CHF | 0.0% |
| 2010 FY | 4.77 Billion CHF | -3.36% |
| 2009 Q4 | 4.94 Billion CHF | 0.0% |
| 2009 FY | 4.94 Billion CHF | 0.24% |
| 2009 Q2 | 5.44 Billion CHF | 0.0% |
| 2008 Q4 | 4.93 Billion CHF | 0.0% |
| 2008 FY | 4.93 Billion CHF | -0.38% |
| 2007 FY | 4.95 Billion CHF | 26.56% |
| 2006 FY | 3.91 Billion CHF | -9.67% |
| 2005 FY | 4.33 Billion CHF | 29.63% |
| 2004 FY | 3.34 Billion CHF | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| American Bio Medica Corporation | 1.26 Million USD | -1346078.093% |
| Arrayit Corporation | 1 Million USD | -1707535.73% |
| Atlantic International Corp. | 4.43 Million USD | -384967.852% |
| Biocept, Inc. | 30.87 Million USD | -55233.139% |
| Bioqual, Inc. | 56.58 Million USD | -30088.443% |
| CardioGenics Holdings Inc | 231.93 Thousand USD | -7365420.929% |
| DermTech, Inc. | 121.93 Million USD | -13910.498% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 4.18 Billion USD | -308.198% |
| HTG Molecular Diagnostics, Inc. | 17.77 Million USD | -95992.539% |
| iMD Companies, Inc. | 190.13 Thousand USD | -8984474.281% |
| IDenta Corp. | 1.52 Million USD | -1116965.276% |
| Interpace Biosciences, Inc. | 13.02 Million USD | -131095.761% |
| Integrative Health Technologies, Inc. | 8.25 Million USD | -206918.663% |
| InVitro International | 1.53 Million USD | -1113519.429% |
| Lumos Diagnostics Holdings Limited | 26.83 Million USD | -63552.284% |
| Many Bright Ideas Technologies Inc. | 2312.00 USD | -738883983.045% |
| Medical Imaging Corp. | 4.19 Million USD | -407450.576% |
| NovelStem International Corp. | 2.25 Million USD | -757613.526% |
| Optigenex Inc. | 1.88 Million USD | -904580.955% |
| PharmChem, Inc. | 2.76 Million USD | -617605.137% |
| Proteome Sciences plc | 14.58 Million USD | -117018.89% |
| Response Genetics, Inc | 48.88 Million USD | -34845.995% |
| Rennova Health, Inc. | 20.57 Million USD | -82936.979% |
| RushNet, Inc. | 6.04 Million USD | -282375.553% |
| ScreenPro Security Inc. | 1.26 Million USD | -1354232.906% |
| Stella Diagnostics Inc. | 472.42 Thousand USD | -3615939.016% |
| StageZero Life Sciences Ltd. | 700.65 Thousand USD | -2438057.602% |
| Todos Medical Ltd. | 15.26 Million USD | -111794.937% |